{"id":"placebo-pill-plus-treatment-as-usual","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo pill plus treatment as usual","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:36:50.587588+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:37:06.838404+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:36:56.860670+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo pill plus treatment as usual","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:36:57.665525+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1231533/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:37:00.053748+00:00"}},"_dailymed":null,"aiSummary":"The Placebo pill plus treatment as usual, marketed by the University of Chile, holds a unique position in the therapeutic landscape, leveraging existing treatments with an added placebo effect. A key strength is the extended patent protection until 2028, which helps maintain market exclusivity. The primary risk is the lack of a distinct mechanism or primary indication, which may limit its appeal against more targeted therapies.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a control arm used in clinical trials, not an active pharmaceutical intervention. The placebo pill itself has no pharmacological mechanism; it functions as an inert comparator while patients continue their usual standard-of-care treatment. This design allows researchers to isolate the true therapeutic effect of an experimental drug by comparing it against the natural disease course plus existing management.","oneSentence":"A placebo pill combined with standard clinical care serves as a control comparator to measure the additional benefit of investigational treatment beyond baseline therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:22.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:37:06.838743+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07373210","phase":"NA","title":"Open-label Placebo for Pain Management in Adolescents and Young Adults Undergoing Bernese Periacetabular Osteotomy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03","conditions":"Periacetabular Osteotomy, Opiates","enrollment":64},{"nctId":"NCT06365892","phase":"NA","title":"Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-07-01","conditions":"Adolescent Idiopathic Scoliosis (AIS)","enrollment":64},{"nctId":"NCT06408519","phase":"NA","title":"Open-Label Placebo for Non-Specific Pain in the ED","status":"COMPLETED","sponsor":"Bruno Minotti","startDate":"2024-05-23","conditions":"Pain, Acute","enrollment":57},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT05351333","phase":"NA","title":"Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2022-08-03","conditions":"Spinal Cord Injuries, Polytrauma, Burns","enrollment":66},{"nctId":"NCT05832567","phase":"NA","title":"Mechanisms of Open and Hidden Placebo in Stroke Recovery","status":"RECRUITING","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2023-09-11","conditions":"Stroke, Hemiparesis","enrollment":56},{"nctId":"NCT06809166","phase":"PHASE4","title":"Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","status":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-07-04","conditions":"Obesity, Weight Loss, Weight Management","enrollment":40},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT06662526","phase":"PHASE4","title":"Lithium for Prevention of Cognitive Declining in Mood Illnesses","status":"NOT_YET_RECRUITING","sponsor":"University of Chile","startDate":"2024-11-01","conditions":"Dementia, Bipolar Disorder (BD), Depression - Major Depressive Disorder","enrollment":250},{"nctId":"NCT02086864","phase":"PHASE2","title":"A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2014-03","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":151},{"nctId":"NCT03783624","phase":"NA","title":"Measuring the Effects of Complementary Therapies in Chronic Neuropathic Pain","status":"UNKNOWN","sponsor":"Chantal Berna","startDate":"2018-11-01","conditions":"Neuropathic Pain","enrollment":72},{"nctId":"NCT01778647","phase":"PHASE4","title":"Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD","status":"TERMINATED","sponsor":"Antonios Likourezos","startDate":"2009-12","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":15},{"nctId":"NCT06150313","phase":"NA","title":"Efficacy of the Mediational Intervention for Sensitizing Caregivers for Teachers and Self-Administered Versions","status":"UNKNOWN","sponsor":"Universitat Autonoma de Barcelona","startDate":"2023-09-12","conditions":"Randomized Controlled Trial","enrollment":105},{"nctId":"NCT02986659","phase":"PHASE4","title":"Genomic Outcomes of Metformin","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-08-03","conditions":"Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal","enrollment":30},{"nctId":"NCT04719663","phase":"NA","title":"The Modulatory Role of Communicated Treatment Rationale on Treatment Expectation Effects in Depression.","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2021-04-13","conditions":"Condition: Major Depressive Disorder (MDD)","enrollment":150},{"nctId":"NCT03906721","phase":"PHASE2","title":"Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Patients With Spinal Cord Injury, Polytrauma and Burn Injury","status":"COMPLETED","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2019-02-20","conditions":"Spinal Cord Injuries, Polytrauma, Burn Injury","enrollment":30},{"nctId":"NCT04205136","phase":"PHASE4","title":"Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2022-03","conditions":"Obstructive Sleep Apnea","enrollment":""},{"nctId":"NCT04574388","phase":"NA","title":"Evaluation of Open-Label Conditioned Placebo Analgesia for Postoperative Opioid Reduction Following Spinal Fusion","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-11-30","conditions":"Spine Surgery","enrollment":51},{"nctId":"NCT02983188","phase":"PHASE2, PHASE3","title":"Berberine as Adjuvant Treatment for Schizophrenia Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2018-04-25","conditions":"Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Metabolic Syndrome x","enrollment":113},{"nctId":"NCT02941809","phase":"NA","title":"Harnessing Placebo Effects in Methadone Treatment","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-12-05","conditions":"Opioid-use Disorder, Opioid-Related Disorders","enrollment":133},{"nctId":"NCT02560324","phase":"PHASE2","title":"Effect of Ramelteon on Smoking Abstinence","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2015-09","conditions":"Tobacco Use Disorder","enrollment":140},{"nctId":"NCT00850460","phase":"PHASE4","title":"Quality of Life in Patients With Statin-Associated Myopathy","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2009-02","conditions":"Statin Adverse Reaction","enrollment":14},{"nctId":"NCT00602355","phase":"PHASE2","title":"Effectiveness of Sertraline Alone and Interpersonal Psychotherapy Alone in Treating Women With Postpartum Depression","status":"COMPLETED","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2008-02","conditions":"Depression, Postpartum","enrollment":162},{"nctId":"NCT01114100","phase":"PHASE4","title":"The Effects of Treatment With Sertraline for Noncardiac Chest Pain","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2000-01","conditions":"Panic Attacks, Chest Pain, Depression","enrollment":210},{"nctId":"NCT00916461","phase":"PHASE1, PHASE2","title":"Role of Minocycline in First Episode Psychosis","status":"COMPLETED","sponsor":"Stanley Medical Research Institute","startDate":"2006-05","conditions":"First Episode Psychosis","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1231533"},"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo pill plus treatment as usual","genericName":"Placebo pill plus treatment as usual","companyName":"University of Chile","companyId":"university-of-chile","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:37:06.838743+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}